Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Telix Pharmaceuticals Ltd. has reported a significant increase in revenue for the first half of 2024, with total revenue growth of 65% driven by strong sales of its prostate cancer imaging agent, Illuccix. The company’s net profit has turned positive, reaching $29.7 million, and they have also announced substantial internal growth and future product launches. These results affirm Telix’s position as a leader in the radiopharmaceutical sector, with a robust pipeline and plans for expansion.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.
